[Skip to Content]
[Skip to Content Landing]
Views 1,145
Citations 0
Invited Commentary
August 28, 2019

Vasopressin as an Early Adjunct to Resuscitation in Hemorrhagic Shock: Crisis AVERTed?

Author Affiliations
  • 1Trauma Research Program, Department of Surgery, Scripps Mercy Hospital, San Diego, California
JAMA Surg. Published online August 28, 2019. doi:10.1001/jamasurg.2019.2905

The job of the modern trauma surgeon faced with a patient in hemorrhagic shock is to balance the competing priorities and demands between resuscitation and restoration of normal perfusion vs the potential adverse effects of resuscitation practices or products. In addition, these therapeutic decisions involve balancing multiple other variables (physiology, active bleeding, brain injury, and organ dysfunction) that are also dynamically changing as therapy is delivered. Thus, hemorrhagic shock in trauma represents an area that is critically in need of high-quality evidence and difficult to model in any standardized study design or protocol. In this issue of JAMA Surgery, Sims and colleagues1 are to be congratulated for performing a high-quality randomized clinical trial examining the addition of low-dose vasopressin (LDV) to the early resuscitation of patients with trauma and hemorrhagic shock (the AVERT Shock Trial). In examining the results of this study, we must consider the direct findings as well as the likely interpretations and extrapolations. The primary direct finding is that the addition of LDV resulted in significantly fewer blood products being administered in the first 48 hours, with a secondary finding of a lower deep venous thrombosis rate in the LDV group.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×